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Binding of short chain phosphatidylserine (C6PS) en-
hances the proteolytic activity of factor Xa by 60-fold
(Koppaka, V., Wang, J., Banerjee, M., and Lentz, B. R.
(1996) Biochemistry 35, 7482–7491). In the present study,
we locate three C6PS binding sites to different domains
of factor Xa using a combination of activity, circular
dichroism, fluorescence, and equilibrium dialysis meas-
urements on proteolytic and biosynthetic fragments of
factor Xa. Our results demonstrate that the structural
responses of human and bovine factor Xa to C6PS bind-
ing are somewhat different. Despite this difference, data
obtained with fragments from both human and bovine
factor Xa are consistent with a common hypothesis for
the location of C6PS binding sites to different structural
domains. First, the -carboxyglutamic acid (Gla) domain
binds C6PS only in the absence of Ca2 (kd  1 mM),
although this PS site does not influence the functional
response of factor Xa. Second, a Ca
2-dependent binding
site is in the epidermal growth factor domains (EGFNC)
that are linked by Ca2 and C6PS binding to the Gla
domain. This site appears to be the lipid regulatory site
of factor Xa. Third, a Ca
2-requiring site seems to be in
the EGFC-catalytic domain. This site appears not to be a
lipid regulatory site but rather to share residues with
the substrate recognition site. Finally, the full func-
tional response to C6PS requires linkage of the Gla,
EGFNC, and catalytic domains in the presence of Ca
2,
meaning that PS regulation of factor Xa involves linkage
between widely separated parts of the protein.
The substantial effects of soluble phosphatidylserine
(C6PS1) on the kinetics of prothrombin activation by factor Xa
(1) and on the structure of factor Xa, as documented here,
indicate that phosphatidylserine (PS) may act as an allosteric
regulator of prothrombin activation. PS located on the cytoplas-
mic face of resting platelet plasma membranes is exposed on
the surface of activated platelet vesicles (2, 3). The implication
of this PS exposure and of the effect of PS on factor Xa and on
its ability to catalyze activation of prothrombin is that PS may
act as a second messenger in regulating thrombin formation.
Because of the crucial role of thrombin in hemostasis, the
exposure of PS may be a crucial regulatory step in blood coag-
ulation. To better define this regulatory process, it is important
to know the locations of the PS binding sites on factor Xa.
The organization of factor X into structural domains is illus-
trated below in Fig. 1. Factor X consists of two peptides. The
light chain consists of an N terminus -carboxyglutamic acid-
rich region (Gla module) and two Cys-rich cassette modules.
The heavy chain consists of the serine protease catalytic do-
main. The two cassette modules of the light chain show strong
sequence and structural homology to epidermal growth factor
(EGF) (4) and are thus referred to as EGFN and EGFC, where
N and C indicate the domain nearer to the N and C termini,
respectively. Crystal structures of Gla domain-less factor Xa
(GDFXa) have been published (5–7). In the most recent of these
(7), the EGF cassette modules extend from the catalytic domain
to make an extended molecule. In the structure of the analo-
gous serine protease, factor IXa, the EGFN module is bent at
the inner-EGFC hinge region to right angles with the EGFC,
which is tucked along the catalytic module (8). It may be that
the EGF modules form a hinge region that modulates the global
structure of factor Xa. The factor IXa structure also differs from
that of GDFXa in containing the Gla domain. Although the Gla
domain is critical for membrane binding and may modulate the
structure of the EGF modules, little is known about the struc-
ture of Gla in whole factor Xa. We have only a model structure
of factor Xa Gla domain based on the prothrombin Gla domain
(9).
Binding of Ca2 to factor X is reportedly required for activa-
tion by factor VIIa/tissue factor or by factor IXa/VIIIa (10, 11)
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and for the activity of factor Xa (12). Ca
2 binding is also
required for PS regulation of factor Xa proteolytic activity (1).
Ca2 binds mainly to the Gla module (13), but there also
appears to be a high affinity Ca2 binding site (kd  160 M) in
the catalytic domain (9, 14–16) and a lower affinity Ca2 bind-
ing site (kd  0.7–1.2 m M) on the isolated first EGF-like
module (4, 12, 16, 17). A Ca2-dependent interaction between
the EGF-like and Gla modules appears to enhance the affinity
of the site on the EGF-like module to the point that it is tighter
(17, 18) (kd  120 M) than the catalytic domain site. Consist-
ent with this, nuclear magnetic resonance shows that Ca2
binding tightens the fold of the isolated EGFN domain and
bends Gla and EGFN domains toward each other around a
hinge located in the Gla domain, referred to as a helical or
hydrophobic stack (19).
Despite considerable information about Ca2 binding to fac-
tor Xa, we have virtually no information about the location of
PS binding sites on this key enzyme. The aims of this work
have been to locate the lipid regulatory site(s) in factor Xa and
to identify the structural domains of factor Xa necessary to see
the C6PS regulatory effect on factor Xa activity.
EXPERIMENTAL PROCEDURES
Materials
1,2-Dicaproyl-sn-glycero-3-phospho-L-serine (C6PS) and 1,2-dica-
proyl-sn-glycero-3-phosphocholine (C6PC) were purchased from Avanti
Polar Lipids Inc. (Alabaster, AL). Russel’s viper venom factor X-
activating protein (RVV-X) was purchased from Hematological Tech-
nologies Inc. (Essex Junction, VT), and factor Xa-specific substrate
N--benzyloxycarbonyl-D-arginyl-L-glycyl-L-arginine-p-nitroanilide
dihydrochloride (S-2765) was purchased from Helena Laboratories
(Beaumont, TX). Chymotrypsin was purchased from Worthington
(Lakewood, NJ). Chromogenetic substrate Spectrozyme PCa (SpPCa)
was purchased from American Diagnostica (Greenwich, CT). [5-(Di-
methylamino)-1-napthalenesulfonyl] glutamylycylarginyl chloromethyl
ketone (DEGR-CK) was purchased from Calbiochem (La Jolla, CA).
Diisopropyl fluorophosphate was purchased from Sigma Chemical Co.
(St. Louis, MO). All other chemicals were ACS reagent grade or the best
available grade.
Methods
Preparation of Factor Xa—Bovine factor X was isolated from a bar-
ium citrate precipitate obtained from freshly collected bovine plasma
(20, 21). Human factor X for stoichiometry and CD measurements was
purified from recovered human plasma obtained from the American
Red Cross, according to the method of Dahlback et al. (22). Factor X
obtained as above was analyzed by SDS-PAGE, concentrated (Centri-
con-10 concentrator supplier), and then stored at 70 °C at a concen-
tration of about 1 mg/ml in 5 mM Tris, 20 mM sodium citrate, 0.6 M NaCl,
pH 7.4. A final purification of factor X was performed 1 day before an
experiment by high-performance liquid chromatography on a
PerkinElmer Life Sciences Isopure LC system using a Mono Q HR 5/5
ion exchange column (Amersham Biosciences, Inc., Norwalk, CN). The
purified factor X was dialyzed into buffer (50 mM Tris, 175 mM NaCl, pH
7.4) for activation. Factor X (10 M) with 5 mM Ca2 was activated at
25 °C with RVV-X that had been covalently linked to agarose beads (10,
23). Factor Xa was purified by high-performance liquid chromatography
on a Mono Q column, and the isolated protein was analyzed by SDS-
PAGE electrophoresis. Factor Xa concentration was measured by deter-
mining the rate of S-2765 hydrolysis in a plate reader-based assay (1),
using active site-titrated factor Xa to construct the standard curve (24).
Purification of Domain Fragments of Bovine Factor Xa—Isolation
and purification of fragments of bovine factor Xa and several of its
structural domains (Gla, EGFN, Gla-EGFN, and Gla-EGFNC) by con-
trolled trypsin digestion were described previously (18, 25, 26).
Preparation of GDFXa, E2FXa, and Y99T—The RSV-PL4 expression
vector was used to express factor X, GDFX, and a construct missing
both the Gla and first EGF domain (E2FX) in human 293 cells (16).
GDFX was also prepared for stoichiometry measurements as described
by Morita and Jackson (27) from isolated factor X. Purified factor X was
reacted with -chymotrypsin (1:400 factor X:-chymotrypsin) at 22 °C
for 45 min, a time sufficient to convert 95% of factor X to GDFX, as
judged by SDS-PAGE on a 6% gel. The reaction was stopped by addition
of 1 mM diisopropyl fluorophosphate, and Gla-domainless factor X was
chromatographed on a Mono Q column. GDFX Y99T mutant was also
prepared as described (28–30). GDFX and its mutant and E2FX were
activated with RVV-X as described earlier (29).
Measurement of Amidolytic Activity of Factor Xa and Its Constructs—
The amidolytic activities of expression products of a human factor Xa
cDNA and of expression products of two of its deletion mutants (GDFXa,
E2FXa) were measured in the presence of 3 mM Ca
2 using the synthetic
substrate S-2765 and the microplate reader-based assay described
above. Samples, containing 20 nM protein, various concentrations of
C6PS and 3 mM Ca2 in a buffer (50 mM Tris, 175 mM NaCl, pH 7.6)
containing 0.6% PEG, were incubated at 37 °C for 15 min before meas-
uring activities. The amidolytic activities were estimated from meas-
ured initial rates of S-2765 hydrolysis, using a standard curve obtained
with active site-titrated factor Xa (1). Amidolytic activities of GDFXa
and Y99T were measured using the chromogenetic substrate Spec-
trozyme PCa (SpPCa) also as described earlier (29). Samples containing
20 nM protein, various concentrations of C6PS (0, 400, 900 M), and
0.6% PEG (to prevent adsorption of protein to the plate) were incubated
in buffer (50 mM Tris, 175 mM NaCl, pH 7.6) in polypropylene
Eppendorf tubes at 37 °C for 5 min before being added to a flat-bot-
tomed polypropylene 96-well plate (Greiner America, Inc.) preincubated
at 37 °C. The initial rates of SpPCa amidolysis were determined on a
Versamax Tunable Microplate Reader (Molecular Devices, Sunnyvale,
CA) at five substrate concentrations (50, 100, 200, 400, and 600 M) and
analyzed in terms of the Michaelis-Menten model using non-linear
regression methods available in Sigma Plot 6.0.
Circular Dichroism Measurements—Circular dichroism (CD) spectra
were generally recorded from 250 to 200 nm on an Aviv Model 620S
spectrometer (Aviv Associates, Inc., Lake Wood, NJ) in a 1-cm path-
length cell at 24 °C with a bandwidth of 1.0 nm. Data points were
collected at every 0.5 nm with an average time of 5 s on each point.
Some data were obtained down to 195 nm on an Applied Photophysics
Pi* spectrometer in a 1-mm path-length cell with a bandwidth of 1 nm
and data collection at every 0.5 nm. Baseline CD spectra of buffer
containing various concentrations of soluble C6PS were collected in the
absence and in the presence of 3 mM Ca2 and were subtracted from
sample spectra. The baseline-corrected digital data were processed,
smoothed, and converted to molar ellipticity, . We have previously
determined the critical micelle concentration (CMC) of C6PS at differ-
ent Ca2 and protein concentrations (1), but controls to detect micelle
formation were in all cases still performed by watching for sudden drops
in ellipticity in the range of 240–250 nm. For human and bovine factor
Xa,
2 the CMC seen in this way was similar to the CMC reported earlier
by quasi-elastic light scattering methods (1). The ellipticity ratio 222/
208 (32) is used here as a convenient parameter to follow changes in
the secondary structure of factor Xa and its fragments upon addition of
C6PS. In addition, we have estimated -helix content using published
software packages CDSSTR and CONTIN (33) to give context to the
222/208 ratio. The ability of CD spectra taken to 200 nm to define
-helix content but not -sheet or turn content is well documented (34).
We could not collect spectra to 185 nm to perform a complete secondary
structure analysis in a buffer containing NaCl, because Na increases
the buffer absorbance in the deep UV (34). Na was necessary in our
studies, because Ca2 binding is required for regulation of factor Xa by
C6PS (1), and Ca2 binding is linked to Na binding (35, 36).
Fluorescence Titration of DEGR-E2FXa by Soluble C6PS—Fluores-
cence intensity measurements were carried out on an SLM 48000
spectrofluorometer (SLM Aminco, Urbana, IL). Slits were closed be-
tween measurements to avoid photodegradation of the sample. All
buffer solutions were filtered using 0.2-m filters (Nalge Co., Rochester,
NY). DEGR-E2FXa was prepared by sequential addition of 5 l of
DEGR-CK (1 mg/ml in 0.02 M Tris, 0.1 M NaCl, pH 7.5) to 1 ml of about
1 M purified factor E2FXa. The extent of labeling at the active site was
followed by the loss of enzymatic activity, as monitored by the S-2765
assay. Labeling was stopped when no activity remained. DEGR-E2FXa
was then dialyzed against 50 mM Tris, 0.1 M NaCl, pH 7.5, to remove
free reagent (37). DEGR-E2FXa (100 nM) in 1.0 ml of buffer (50 mM Tris,
pH 7.5) was incubated in a stirred micro-cuvette (Hellma Cells,
Jamaica, NY) with 0.15 mM NaCl or 3 mM Ca2 or both at 25 °C for 20
min. Following additions of C6PS (1–2 l each addition for a maximum
of 4% dilution) and an equilibration of at least 4 min, fluorescence
intensity was recorded using an excitation wavelength of 340 nm (band-
pass 8 nm) and an emission wavelength of 550 nm (bandpass 4 nm). For
each addition, several intensity measurements were performed and
averaged and corrected for dilution. Control experiments were per-
2 J. Wang, R. Majumder, and B. R. Lentz, submitted for publication.
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formed in which buffer was titrated with soluble lipid in the absence of
protein. The lipid solution showed very minor background fluorescence
or light scattering signal (which was subtracted from sample signal)
until the critical micelle concentration was reached. The critical micelle
concentration for C6PS in the presence and absence of 1 M factor Xa
were determined previously to be 0.95 and 2.5 mM, respectively (1). The
critical micelle concentrations for C6PC under similar conditions were
even higher (1). Data were not analyzed above the critical micelle
concentration.
Intrinsic Fluorescence of Gla-EGFNC—Gla-EGFNC (100 nM) in 50 mM
Tris, 150 mM NaCl, pH 7.4, in the presence and in absence of 3 mM Ca2
was titrated with soluble C6PS, and the intrinsic fluorescence was
monitored at 345 nm (bandpass 4 nm) followed by excitation at 285 nm
(bandpass 8 nm). Control experiments were as mentioned for DEGR-
E2FXa fluorescence.
Phospholipid Sample Preparation—C6PS and C6PC solutions were
prepared from measured quantities of 10 mg/ml stock solutions in
chloroform. The chloroform was evaporated under a stream of nitrogen.
The lipid was re-dissolved in cyclohexane, and this solution was frozen
on the wall of a capped test tube and then lyophilized overnight. The
resulting dry powder was dispersed in the appropriate volume of buffer
and vortexed thoroughly to reach a concentration of 100 mM. The final
concentration of this phospholipid stock solution was determined by an
inorganic phosphate assay (38).
Determination of the Stoichiometry of C6PS Binding to Various Frag-
ments of Factor Xa—The stoichiometries of soluble C6PS binding to
factor Xa, GDFXa, Gla-EGFNC, and Gla in the absence and in the
presence of 3 mM Ca2 were determined by equilibrium dialysis meas-
urements. This procedure not only establishes stoichiometry but also
confirms indirect binding results by a direct measurement. Experi-
ments were performed using 2.0-ml Teflon dialysis cells (Spectrum
Medical, Los Angeles, CA) with the two cells separated by a 2000
molecular weight cut-off membrane. Both chambers contained equal
amounts of C6PS, enough to saturate 85% of the protein present in
one-half of the dialysis cell at varying concentrations (30–100 M). The
lipid concentrations used depended on the crude binding constants
estimated in CD titrations. Depending on the particular combination of
lipid and protein concentration in a given experiment and on the stoi-
chiometry of binding for a particular peptide, between 79 and 94% of
lipid remained unbound at equilibrium. The two chambers were al-
lowed to equilibrate at room temperature for 24 h while being rotated
horizontally at 20 rpm. The protein concentration gradient between the
two halves of the cell causes a difference in the total phosphate concen-
tration between the two halves of the cell. The concentration of protein-
bound C6PS was measured as the difference in total phosphate concen-
tration (P) (38) between the two chambers of the dialysis cell.
Assuming a simple model of binding of lipid to n equivalent and inde-








where [L] is free lipid concentration and kd/n is the observed stoichio-
metric dissociation constant for lipid binding, assuming a single site
model. For [L]  kd/n, this is roughly a straight line with a slope
proportional to n. In our experiments, we maintained [L]  kd/n, but the
total lipid concentration had to remain less than the CMC of the lipid.
Thus, to obtain n, we had to fit a plot of P versus protein concentration
to the non-linear equation given in Equation 1, using standard non-
linear regression procedures and the program SigmaPlot (version 6 for
Windows 2000; Jandel Scientific).
Data Analysis
In our experiments, soluble lipid was added to the protein solution,
and the observed response was taken as representing the fraction of





where Kd is the apparent stoichiometric binding constant for soluble
lipid binding to the protein. Any observable value that changes from an
initial value of R0 to a final value at saturation, Rsat, as a result of






 f (Eq. 3)
RESULTS
Effect of Soluble C6PS on the Amidolytic Activities of Human
Factor Xa and Its Deletion Constructs—We have shown previ-
ously that C6PS enhances proteolytic activity of human factor
Xa by roughly 60-fold but inhibits the amidolytic activity to-
ward S-2765 by 60% (1). The variation of amidolytic activity of
expressed human factor Xa, GDFXa, and E2FXa (Fig. 1) in the
presence of 3 mM Ca2 with soluble C6PS concentration is
shown in Fig. 2. The highest C6PS concentration used (0.8 mM)
was still below the CMC for C6PS in the presence of 3 mM Ca2
(2.5 mM) (1). The amidolytic activities of factor Xa and GDFXa
were decreased by 79 and 9%, respectively, at saturation with
C6PS (Table I), but C6PS had negligible effect on the amidol-
ytic activity of E2FXa. The functional responses of factor Xa and
its constructs to C6PS binding were reasonably well described
by a single binding site model (see “Methods”), and the binding
parameters are given in Table I. The apparent Kd for C6PS
binding to the expressed human factor Xa in this experiment
(39 	 6 M) was comparable to but somewhat smaller than we
have reported previously for factor Xa isolated from outdated
human plasma (65 	 5 M) (1), and the percent inhibition was
also greater (80 versus 60%). This probably reflects the slight
difference between Xa from human plasma and factor Xa from
a single cDNA clone, as used here.
Effect of Soluble C6PS on the CD Spectra of Expressed Hu-
man Factor Xa and Its Constructs—The effects of soluble C6PS
on the CD spectra of expressed human factor Xa and its con-
structs, GDFXa and E2FXa, were studied in the absence and
presence of 3 mM Ca2. CD spectra of human factor Xa are
shown at various concentrations of C6PS in the presence (Fig.
3A) and in the absence of 3 mM Ca2 (Fig. 3B). Although it is
reported to bind Ca2 (17), human factor Xa did not undergo a
detectable change in secondary structure upon addition of 3 mM
Ca2, as seen from the solid and dotted curves in Fig. 3A and
from the 222/208 ratio and -helical content (Table I). Sec-
ondary structure analysis yielded an estimate of 11% helical
content in the presence or absence of Ca2, in good agreement
with the reported helicity for the analogous factor IXa crystal
structure (10.6%) (8). However, there was a substantial change
in CD upon addition of C6PS to human factor Xa in the pres-
ence of 3 mM Ca2 (Fig. 3A). By contrast, there was only a small
change in CD upon addition of C6PS in the absence of Ca2.
The variation of ellipticity ratio (222/208) for human factor Xa
with C6PS concentration is shown as an inset in Fig. 3 (A and
B) in the presence and absence of Ca2, respectively.
The variations of ellipticity ratio of GDFXa and E2FXa with
C6PS concentration are shown in Fig. 4 (B and C, respectively).
The smooth lines through the data result from fitting the data
to a single-binding-site model as described under “Methods.”
The stoichiometric binding constants (Kd) and percent changes
in 222/208 at saturation (Rsat/R0 
 100%), resulting in the
least square fits, are reported in Table II. We stress that Kd
values obtained in this way cannot be interpreted as site bind-
ing constants (kd), because the number of data points taken and
their intrinsic accuracy were not sufficient to define a binding
mechanism in terms of the number, affinities, and responses of
different sites present on each peptide fragment. However, the
data in Fig. 4 do establish, in most cases, which fragments do
bind C6PS, the magnitude of the total response (shifts in sec-
ondary structure), and the fraction of sites occupied at any lipid
concentration (from Kd values). The ellipticity ratio of factor Xa
decreased by 6% upon saturation with C6PS in the absence of
Ca2 and by 16% when saturated with C6PS in the presence of
3 mM Ca2. Similarly, the -helical content decreased by 1 and
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3%, respectively (Table II). There was an 18% decrease in
222/208 ratio of GDFXa but only a slight (0.8%) decrease in
helical content in response to soluble C6PS in the presence of 3
mM Ca2. This discrepancy between changes in 222/208 and
helical content suggests that GDFXa binding to C6PS involves
more than a change in helical content. Neither the 222/208
ratio nor the -helix content changed upon addition of C6PS in
the absence of Ca2(Fig. 4B, Table I). Human GDFXa seems to
bind soluble C6PS in the presence of 3 mM Ca2, with its
structural response being comparable to that of whole human
factor Xa, but seems not to bind C6PS in the absence of Ca
2,
at least not with a measurable structural response. The 222/
208 ratio of E2FXa decreased by 10% upon addition of satu-
rating concentrations of C6PS in the presence of 3 mM Ca2 but
remained unchanged in the absence of Ca2. The 10% decrease
in ellipticity ratio was significantly smaller than that seen
either for native human factor Xa (16%) or for GDFXa (16%).
Effect of Soluble C6PS on the CD Spectra of Bovine Factor Xa
and Its Domains—The CD spectra of bovine factor Xa and its
Gla, EGFN, Gla-EGFN, and Gla-EGFNC domains were also
collected and analyzed in terms of 222/208 and -helical
content. The variations of ellipticity ratio (222/208) with
C6PS concentration in the presence (closed circles) and absence
(open circles) of 3 mM Ca2 for factor Xa, Gla, Gla-EGFN, and
Gla-EGFNC domains, are shown in Fig. 4 (A, D, E, and F,
respectively). The smooth curves through these data result
from fitting the data to a single-site binding model (see “Meth-
ods”), with binding constants (Kd) and fractional changes in
222/208 at saturation (Rsat) reported in Table II. The 222/
208 ratio of bovine factor Xa decreased by 16% upon addition
of saturating concentration of C6PS in the absence of Ca2 but
increased by 26% in the presence of 3 mM Ca2 (Table II). These
same spectra were analyzed to reveal changes in -helical
content of 1 and 6%, respectively (Table II).
Comparison of changes in -helical content with changes in
222/208 ratios for human and bovine factor Xa and their
FIG. 2. The effect of soluble C6PS on amidolytic activities of
human factor Xa and its constructs, GDFXa and E2FXa. The initial
rates of S-2765 amidolysis by factor Xa (hexagons), GDFXa (circles), and
E2FXa (triangles) are plotted as a function of C6PS concentrations in the
presence of 3 mM Ca2. Rates were measured at 37 °C in a buffer
containing 50 mM Tris, 175 mM NaCl, 0.6% PEG, at pH 7.6. Absolute
amidolytic activities of human factor Xa, GDFXa, and E2FXa in the
absence of C6PS were 1.40, 0.83, and 0.79 mM S-2765/s/M enzyme,
respectively. The absolute activities were calculated based on an extinc-
tion coefficient for S-2765 of 1.39 OD/M at 405 nm.
TABLE I
Parameters describing binding of soluble C6PS to human factor Xa





Human Xa 39 	 6 79
Human GDFXa 86 	 18 9
Human E2FXa NA
c 0
a Kd, apparent stoichiometric dissociation constant.
b Rsat, percent change in activity upon addition of saturating con-
centration of C6PS.
c NA, not applicable.
FIG. 1. Domain structure of factor Xa and summary of results. Schematic diagram of the domain structure of human factor Xa. The N
terminus contains a region rich in -carboxyglutamic acid responsible for membrane binding (Gla domain). The epidermal growth factor domains
(EGFN and EGFC) and the catalytic domain are also shown. The construct missing the Gla domain is referred to as GDFXa, and the domain missing
both the Gla and EGFN domains is called E2FXa. Results in the absence of Ca
2 are summarized below the factor Xa diagram: bovine Gla,
Gla-EGFN, and Gla-EGFNC CD spectra all responded to C6PS. Stoichiometry measurements showed that Gla domain binds to one molecule of
C6PS, whereas the Gla-EGFNC domain binds to two molecules. Neither stoichiometry nor CD measurements showed an interaction of C6PS with
human E2FXa or GDFXa. Factor Xa binds one molecule of C6PS, an interaction confirmed by CD. Results in the presence of Ca
2 are summarized
above the factor Xa diagram: bovine Gla and Gla-EGFN did not bind to C6PS, but Gla-EGFNC binds one molecule of C6PS and also showed a change
in CD spectrum and intrinsic fluorescence with C6PS. Human E2FXa, GDFXa, and factor Xa all showed altered CD spectra with C6PS. GDFXa and
factor Xa each bind two molecules of C6PS, and their amidolytic activities were sensitive to the presence of C6PS. Although E2FXa binding to C6PS
was detected with CD and fluorescence, its amidolytic activity was unchanged with the addition of C6PS.
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fragments (Table II) makes it clear that there is a general
correlation between these two parameters, but that the 222/
208 ratio reflects more than just helical content. It is also clear
from comparison of the responses of bovine and human factor
Xa to C6PS that the secondary structural changes associated
with C6PS binding are different for these two proteins (Table
II). However, CD spectra for bovine Xa taken under the same
conditions used for the spectra in Fig. 3 were qualitatively
similar to the human Xa spectra shown in Fig. 3. To make a
more quantitative comparison of these two proteins, we col-
lected spectra down to 185 nm in a buffer identical to that used
for Fig. 3, except it lacked NaCl and was therefore much more
transparent in the deep UV spectrum (34). Dialysis of bovine
factor Xa into this buffer and then return to a normal 150 mM
NaCl buffer over a period of 48 h had no measurable effect on
the ability to bind C6PS or on the amidolytic activity of factor
Xa toward S-2765 substrate. Secondary structure analysis of
the bovine and human protein spectra in a NaCl-free buffer
revealed no difference between the two of greater than 0.9% of
helical, beta, turn, or unstructured content. As expected, be-
cause Na is needed for Ca2 binding (35, 36) and Ca2 is
needed for C6PS binding (1), there was no significant change in
secondary structure content upon addition of either Ca2 or
C6PS to either protein in the buffer lacking NaCl. Thus, spec-
tra of this quality could not be used to quantitate the different
effects of C6PS on bovine and human factor Xa secondary
structure, but were useful to establish the expected structural
similarity between these two analogous proteins.
The ellipticity ratio of the Gla domain increased by 43%,
while -helicity increased by 1.8% upon addition of 3 mM Ca2
(Fig. 4D at 0 mM C6PS). In the absence of Ca2, the ellipticity
ratio increased by 97% at saturation with C6PS while -helic-
ity increased by 2.1% (Table II). However, no measurable
change was seen in the presence of 3 mM Ca2. This suggests
the presence of at least one Ca2-masked soluble lipid binding
site in the Gla domain of bovine factor Xa but no Ca
2-depend-
ent site. This site was not specific for PS, because C6PC also
bound to the Gla domain in the absence of Ca2 (data not
shown).
Ca2 bound to the EGFN domain of factor Xa and induced a
large decrease in the ellipticity ratio (81%) but no change in the
-helical content (Table II). This is not surprising, because the
solution structure of bovine factor Xa EGFN is reported to
consist almost entirely of anti-parallel -sheets and turns (39)
and Ca2 binding to Gla-EGFN seems not to alter its fold (19).
This is another example of how the 222/208 ratio reflects
more than the -helical content of a protein, and, in this case,
must reflect Ca2-induced structural rearrangements that al-
ter the electronic symmetry of EGFN. By contrast to Ca
2,
C6PS had no effect on the EGFN spectrum (data not shown)
FIG. 3. A, the effect of C6PS on the CD spectrum of human factor Xa
in the presence of 3 mM Ca2. Human factor Xa (0.6 M) was examined
at 24 °C in 1.0 mM Tris, 150 mM NaCl, pH 7.4, buffer (solid line), and in
the presence of 3 mM Ca2 (dotted line), 3 mM Ca2 plus either 0.2 mM
C6PS (dashed line) or 0.6 mM C6PS (dot-dashed line). The CMC of C6PS
under the conditions of this experiment was estimated to be between
600 and 800 M, based on changes in the ellipticity between 245 and 250
nm (see “Methods”). The variation of 222/208 with C6PS in the pres-
ence of 3 mM Ca3 is shown in the inset. B, the effect of C6PS on the CD
spectrum of human factor Xa in the absence of Ca
2. Human factor Xa
(0.6 M) was examined as above in the presence of 0 mM (solid line), 0.2
mM C6PS (dashed line), or 0.6 mM C6PS (dot-dashed line), but in the
absence of Ca2. The variation of 222/208 with C6PS in the absence of
Ca3 is shown in the inset. Solid lines shown in the insets result from
fitting the data to a single-binding-site model (“Methods”) with the
best-fit parameters given in Table II.
FIG. 4. The variations of ellipticity ratio (222/208) with C6PS
concentration. A, bovine factor Xa; B, human GDFXa; C, human
E2FXa; D, bovine Gla; E, bovine Gla-EGFN; F, bovine Gla-EGFNC. In
each panel, data are presented as collected in the presence of 3 mM Ca2
(filled circles) and in the absence of Ca2 (open circles). Solid lines show
the results of fitting the data to a single-binding-site model (“Methods”)
with the best-fit parameters given in Table II.
TABLE II
Parameters describing binding of soluble lipids to various domains of
human and bovine factor Xa in the presence and absence






Human Xa 31 	 10
c 16 11.138.2
Bovine Xa 304 	 16
c 26 11.3317.0
Human GDFXa 130 	 10
c 18 6.135.3
Human E2FXa 88 	 8
c 10 6.135.6






Bovine Gla NAd 0 15.6315.9
No Ca2
Human Xa 61 	 8
c 6 11.0310.1






Bovine Gla-EGFNC 486 	 18
c 121 9.7312.5




Bovine Gla 960 	 28c 97 13.8315.9
a Calculated as the percent change in observable at saturating lipid,
i.e. sat  (Rsat  R0)/R0 
 100%. R  222/208.
b Changes in the percent helicity estimated by fitting the CD spectra
by two different algorithms (33). The disparity between estimates by
the two methods was always 10% of the estimates.
c Parameter uncertainty based on non-linear regression.
d NA, not applicable.
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either in the presence or in the absence of Ca2 (Table II). The
Gla-EGFN domain pair also bound to Ca
2 and induced a 140%
increase in ellipticity ratio (Fig. 4E). In terms of secondary
structure, this translated into a large increase in 222/208 and
a nearly insignificant decrease in -helical content (Tables I
and II). It is known from NMR studies that Gla-EGFN under-
goes a significant structural reorganization in which the EGF
and Gla domains fold onto each other upon binding Ca2 (19).
C6PS induced a structural change in Gla-EGFN in the absence
of Ca2 (222/208 increased by 333% and helicity increased by
2.3%; Fig. 4E and Table II), but no C6PS-dependent change
was detected in the presence of 3 mM Ca2. The change in
222/208 seen in the absence of Ca
2 was much greater than
seen for the Gla domain (Table II). Because EGFN showed no
change in response to C6PS, this implies that C6PS binding to
Gla-EGFN in the absence of Ca
2, like the binding of Ca2 in
the absence of C6PS (19), involves linkage between the Gla and
EGFN domains.
Unlike Gla-EGFN, Gla-EGFNC interacted with soluble C6PS
in the presence of Ca2 (222/208 increased by a barely per-
ceptible 10% while helicity also increased by only 1.1%) as well
as in its absence (222/208 and helicity increased by 121 and
2.8%, respectively).
Stoichiometry of C6PS Binding to Factor Xa and Its Frag-
ments—To test and extend our CD observations, C6PS binding
to bovine and human factor Xa and their fragments was also
monitored by equilibrium dialysis, a direct binding measure-
ment. Because of the large quantities of protein needed for
these measurements, it was not possible to obtain complete
binding isotherms by this method. However, using dissociation
constants estimated from our CD data, it was possible to esti-
mate binding stoichiometries (see Equation 1 under “Meth-
ods”). The measured stoichiometries of C6PS binding to various
fragments in the presence and in the absence of 3 mM Ca2 are
shown in Table III. Human factor Xa binds two molecules of
C6PS in the presence and one in the absence of 3 mM Ca2,
respectively, just like bovine factor Xa.
2 Human Gla domain-
less factor Xa (GDFXa) also bound two molecules of C6PS in the
presence of Ca2 but did not bind to C6PS in the absence of
Ca2. The bovine Gla domain bound one molecule of C6PS in
the absence of Ca2 and did not bind C6PS in the presence of 3
mM Ca2, consistent with the lack of any change in 222/208
under these conditions (Fig. 4D). When the Gla domain was
linked to the EGFNC domain, it bound two molecules of C6PS in
the absence and one molecule of C6PS in the presence of 3 mM
Ca2. Stoichiometry measurements were thus all consistent
with the results of our CD experiments. Together, these results
provide a clear and self-consistent picture of the distribution of
C6PS binding sites on factor Xa (Fig. 1).
Fluorescence of Gla-EGFNC Titrated with C6PS—Because
the C6PS-induced change in secondary structure in the Gla-
EGFNC domain triplet was so small (Fig. 4F), we tested further
for a C6PS-induced conformational change by titrating the
intrinsic fluorescence of Gla-EGFNC with soluble C6PS in the
absence (open circles) and presence (closed circles) of 3 mM
Ca2, with the results shown in Fig. 5. The curves passing
through the data were obtained by fitting the data to the single
binding site model (see “Methods”). The apparent stoichiomet-
ric binding constants for C6PS binding to Gla-EGFNC in the
presence and absence of Ca2 were 203 	 63 and 470 	 74 M,
respectively. These binding constant are comparable to those
obtained by CD measurements (Table II). We conclude that
Ca2-dependent binding of C6PS produced conformational
changes in the Gla-EGFNC domain triplet.
Fluorescence of DEGR-E2FXa Titrated with C6PS—Although
CD data suggest that a Ca2-requiring site might be located in
the E2FXa fragment, we could not confirm this by direct stoi-
chiometry measurement due to a lack of sufficient quantities of
this expressed protein. To confirm the Ca2-requiring binding
site in to the E2FXa fragment, we labeled E2FXa with
DEGR-CK and monitored the change of fluorescence intensity
of DEGR-E2FXa as a function of C6PS. The binding analysis
was performed with two preparations of DEGR-E2FXa, and the
results are presented in Fig. 6, with the results from the two
preparations distinguished by closed circles and closed squares.
The results clearly show a saturable drop in DEGR- E2FXa
fluorescence in the presence of Na and Ca2, although no
change was detected when either Ca2 (open triangles) or Na
(open circles) were missing. This requirement for Na2 and
Ca2 for C6PS binding to E2FXa raises the possibility that the
site in the E2FXa fragment might be the amine binding site
that is also reported to require Ca2 and Na (40). A global fit
of a single-site binding model to the two data sets obtained in
the presence of both Na2 and Ca2 is shown by the solid
hyperbolic curve.
Effect of Soluble C6PS on the Amidolytic Activities of Ex-
pressed Human GDFXa and Its Mutant Y99T—To better es-
tablish the identity of the C6PS site located in the E2FXa
fragment, we monitored hydrolysis of SpPCa by GDFXa and its
mutant Y99T as a function of soluble C6PS, in buffer lacking
Ca2. Monnaie et al. (40) showed that an amine binding site
TABLE III
Stoichiometry determination for soluble C6PS binding to various
fragments of human and bovine factor Xa in the presence and absence
of 3 mM Ca2
Species Stoichiometry C6PS concentrationused
M
3 mM Ca2
Human Xa 1.75 	 0.03 400
Human GDFXa 1.96 	 0.09 600
Bovine Gla-EGFNC 0.97 	 0.07 400
Bovine Gla NCa 400
No Ca2
Human Xa 0.93 	 0.07 400
Human GDFXa NC
a 600
Bovine Gla-EGFNC 1.76 	 0.05 800
Bovine Gla 0.96 	 0.12 400
a No change in lipid concentration detected between two chambers,
i.e. no binding detected.
FIG. 5. Response of Gla-EGFNC intrinsic fluorescence to titra-
tion by soluble C6PS. 100 nM bovine Gla-EGFNC was titrated with
soluble C6PS in a buffer containing 50 mM Tris, 150 mM NaCl at pH 7.4
in the presence of 3 mM Ca2 (closed circles) and in the absence of Ca2
(open circles). Fluorescence intensities of Gla-EGFNC were measured
following an equilibrium period of 4 min after each addition of C6PS.
The curves passing through the data were obtained by fitting the data
to a single binding site model (see “Methods”), yielding dissociation
constants for C6PS binding to Gla-EGFNC in the presence and in the
absence of Ca2 of 203 and 470 M, respectively.
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exists in the catalytic domain and shares at least some residues
with the substrate binding site. Like binding of C6PS, this site
was both Ca2- and Na-dependent. The variation of amidol-
ytic activities as a function of C6PS concentrations is shown in
Fig. 7. As expected, because no C6PS binding site was detected
in GDFXa in the absence of Ca2, soluble C6PS did not have
any effect on the rate of hydrolysis of SpPCa by GDFXa (closed
triangles). However, the rate of hydrolysis of SpPCa by the
Y99T GDFXa mutant decreased with the addition of C6PS, and
the binding curve (open triangles) was fitted to a single-bind-
ing-site model with an apparent stoichiometric dissociation
constant of 410 M. It appears that the Ca2-requiring C6PS
binding site in GDFXa becomes independent of Ca
2 as a result
of the Y99T mutation. This result clearly proves that residue
Tyr-99, which is known to be part of a reported amine binding
site and the substrate binding site (40), plays a role in C6PS
binding to the Ca2-requiring site located in the E2FXa frag-
ment. The question still remains: Are the C6PS site and the
substrate binding site are one and the same? To answer this
question, we monitored the effect of C6PS on the kcat and KM for
SpPCa hydrolysis by Y99T GDFXa in the absence of Ca
2. As
shown in the inset in Fig. 7, kcat remained constant with C6PS
concentration but KM increased in a hyperbolic fashion with an
increase in lipid concentration. This means that C6PS com-
petes with substrate for the substrate binding site, just as
tertiary amines have been shown to do (40). We conclude that
the Ca2-requiring C6PS binding site shares some ligand-rec-
ognition residues with the substrate binding site. We report
elsewhere that the Ca2-requiring site minimally recognizes
glycerolphosphorylserine and does not bind phosphatidylcho-
line.3 Because the amine binding site recognizes choline (40), it
is unlikely that the C6PS site and the amine site are identical,
but they likely share some ligand recognition regions with each
other and with the substrate binding site.
DISCUSSION
We have shown previously (1) that soluble C6PS enhanced
factor Xa’s proteolytic activity by about 60- to 70-fold. The
purpose of this work was to locate the C6PS effector sites to one
or more domains of factor Xa. Our results have located three
sites on this serine protease but suggest that only one is in-
volved in functional regulation. These results support a rea-
sonable hypothesis for how one molecule of regulatory C6PS
and two molecules of non-regulatory C6PS are bound to factor
Xa. This hypothesis is summarized in Fig. 1. The arguments in
favor of this hypothesis are summarized below.
One Ca2-masked Phospholipid Site Is Located in the Gla
Domain—As expected (42), the secondary structure of the Gla
domain was sensitive to the presence of 3 mM Ca2 (compare
open and closed circles of Fig. 4ID at 0 mM C6PS) with the
change elicited by Ca2 being a 43% increase in 222/208 and
a 1.8% increase in -helical content. However, the C6PS site in
the Gla domain was masked by Ca2, because no structural
response was seen (Fig. 4D). This is surprising, because bind-
ing of Gla-containing proteins to PS-containing membranes has
long been seen as mediated by a Ca2-induced conformational
change of the Gla domain (43–46). It may be that binding of
Gla-containing proteins to a PS-containing membrane involves
adsorption of the Ca2-conformation of the Gla domain to a
membrane surface (31, 47–48) rather than recognition of indi-
vidual PS molecules by specific binding sites. By contrast, the
C6PS-induced conformational change that we see in the ab-
sence of Ca2 does involve a single C6PS molecule (Table III).
Because neither human (1) nor bovine factor Xa
2 respond func-
tionally to C6PS in the absence of Ca2, it is unlikely that this
Ca2-masked site could by itself be a regulatory site.
Two C6PS Sites Exist in the Factor Xa Fragment that Lacks
the Gla Domain (GDFXa)—Our stoichiometry measurements
showed that GDFXa binds two molecules of C6PS in the pres-
ence of 3 mM Ca2 (Table III). Both of these sites are Ca2-de-
pendent, because there was no detectable change in 222/208
(Fig. 4B, open circles), and the stoichiometry was nearly zero
(Table III) in the absence of Ca2, meaning binding of C6PS in
the absence of Ca2 is at best quite weak.
The EGF and Gla Domains Are Structurally Linked by C6PS
Binding—The EGFN domain alone did not respond structurally
to C6PS, in either the presence or absence of Ca2 (Table II). In
the absence of Ca2, however, when linked covalently to the
Gla domain, the EGFN domain either experienced a large con-
formational change (222/208  333%) or modified in a major
way the response of the Gla domain (222/208  97%) to
C6PS. Based on a comparison of the structural changes for Gla
and Gla-EGFN and on the low helical content of these two
domains in homologous factor IXa (8), it would appear most
likely that the response being monitored in Gla-EGFN is not
3 M. Banerjee, D. C. Drummond, A. Srivastava, D. Daleke, and B. R.
Lentz, submitted for publication.
FIG. 7. The effect of soluble C6PS on the amidolytic activities
of expressed human GDFXa and its mutant Y99T. The initial rates
of SpPCa amidolysis by GDFXa (closed triangles) and Y99T (open tri-
angles) in the absence of Ca2 are plotted as a function of C6PS con-
centrations. Rates were measured at 37 °C in a buffer containing 50 mM
Tris, 175 mM NaCl, 0.6% PEG, at pH 7.6. The hyperbolic line passing
through the Y99T data was obtained by fitting the data to the single-
binding-site model, which yielded a dissociation constant of 410 	 88
M. The initial rates of Y99T amidolysis were determined at 0, 400, and
900 M C6PS concentrations and at 50, 100, 200, 400, and 600 M
substrate concentrations. From these data, we determined the kcat and
KM values for SpPCa amidolysis by Y99T at these three lipid concen-
trations. The variation of kcat/kcat0 (circles) and KM (squares) with the
C6PS concentration is shown in the inset.
FIG. 6. Response of DEGR-E2FXa fluorescence to titration by
soluble C6PS. 100 nM human DEGR-E2FXa was titrated with soluble
C6PS in buffers: 50 mM Tris, 3 mM CaCl2, and 150 mM NaCl (closed
circles and closed squares representing two independent preparations of
DEGR-E2FXa); 50 mM Tris, 3 mM CaCl2 (open circles); and 50 mM Tris,
150 mM NaCl (open triangles) at pH 7.4. Fluorescence intensities were
measured 4 min after each addition of C6PS. A global fit of a single-site
binding model to the two data sets obtained in the presence of both
Na2 and Ca2 is shown by the solid hyperbolic curve and yielded a
dissociation constant of 27 	 5 M.
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that of the Gla domain and is not a change in -helix content,
but is a change in the EGFN module that requires conforma-
tional linkage to the Gla domain. Like Gla, Gla-EGFN did not
bind C6PS in the presence of Ca2, so the Gla-EGFN site seen
in the absence of Ca2 must involve the Ca2-masked site in
the Gla domain. Ca2-mediated conformational linkage be-
tween the Gla and EGFN domains of factor Xa is well estab-
lished (14, 19), and our results imply that this linkage involves
a C6PS binding site as well.
Unlike the Gla-EGFN fragment, the Gla-EGFNC fragment
experienced a structural change induced by C6PS both in the
presence and absence of Ca2, although the changes seen in the
presence of Ca2 were qualitatively different from those seen in
its absence (Figs. 4F and 5). Stoichiometry measurements
showed that Gla-EGFNC binds one C6PS molecule in the pres-
ence of Ca2 and two in the absence of Ca2 (Table III). Based
on these observations, Gla-EGFNC seems to have two types of
C6PS sites. One is the Ca2-masked site in the Gla domain,
and one is a site that does not require Ca2 to recognize C6PS
but that binds C6PS much more tightly in the presence of Ca2
than in its absence (Table II and Fig. 5). The Ca2-dependent
site requires linkage of all three N-terminal modules (Gla,
EGFN, and EGFC) for a full response. Ca
2 is known to link the
EGFN and Gla domains (14, 19), and Ca
2 masks the C6PS site
in the Gla domain. For these reasons, we suggest that Ca2
links the C6PS sites in the Gla-EGFN and EGFNC domains to
create one site having higher affinity for C6PS than either of
the individual sites. If so, we expect that the sandwich formed
by the Ca2-linked Gla and EGFN domains (19) will form an
important element of this binding site.
A Ca2-requiring Site in the EGFC-catalytic Domain Is Prob-
ably Part of the Substrate Recognition Site—Direct measure-
ment of stoichiometry by equilibrium dialysis measurements
showed two C6PS binding sites in GDFXa in the presence of
Ca2 and none in the absence of Ca2 (Table III). We know that
one of these Ca2-dependent sites must be in the EGFNC pair.
A Ca2-requiring site is in the E2FXa fragment (Figs. 4C and
6). Our experiment with the Y99T mutant of GDFXa showed
that C6PS binding to the Ca2-requiring site in the E2FXa
fragment competes with binding of substrate (inset to Fig. 7). In
addition, C6PS binding to GDFXa was altered by the Y99T
mutation and Y99 is known to be part of the substrate recog-
nition site (40). From these observations, we conclude that the
Ca2-requiring C6PS site in E2FXa at least overlaps the sub-
strate recognition site. This is consistent with the fact that
substrate recognition is also linked to Na and Ca2 binding
(35, 36). Because this site is located roughly 60 Å from the
membrane surface (37), it is unlikely to be involved in regulat-
ing activity in vivo.
The Functional Response to C6PS Seems to Require Mini-
mally the EGFNC Pair and the Catalytic Domain—It is known
that the proteolytic activity of factor Xa is enhanced roughly 60-
to 70-fold by binding of C6PS (1). The change in amidolytic
activity of the GDFXa fragment upon titration with C6PS
clearly followed a single-site-binding model (Fig. 2), suggesting
either that only one site regulates activity or that the two sites
are equivalent in their abilities to modulate activity. This frag-
ment consists of a pair of EGF-like domains and a catalytic
domain. Our data show that one C6PS site is located at or near
the substrate recognition site (Fig. 7) and that one site is most
likely in the EGFNC pair (Fig. 1 and Tables I–III). It appears for
three reasons that regulation of activity by C6PS requires the
site in the EGFNC pair. First, the substantial amidolytic activ-
ity toward S-2765 of the E2FXa fragment did not respond to
C6PS (Fig. 2), although E2FXa did undergo a C6PS-induced
conformational change that required Ca2 (Fig. 6). Second, the
Kd for the Ca
2-dependent structural response of bovine Gla-
EGFNC to C6PS (155 M, Table II) was similar to that for the
activity response of bovine factor Xa (167 M).
2 Finally, the site
in the EGFNC pair can be occupied in the presence or absence
of Ca2 (see Figs. 4F and 5 and Table II), but with very
different Kd values and structural responses under these two
circumstances (Table II). In the absence of Ca2, the response
to C6PS seems to depend only on the linkage of Gla to EGFN,
while in the presence of Ca2, the complete EGFNC pair is
needed. Because factor Xa is active only in the presence of Ca
2,
we conclude that the site that regulates activity requires both
the EGF domains. The fact that the response of GDFXa activity
to C6PS was only about a tenth that of whole factor Xa implies
that the regulatory site is in the EGFNC domain but that
linkage to the Gla domain is essential for optimal changes in
the catalytic domain’s active site.
Bovine and Human Factor Xa Have Analogous C6PS Binding
Sites—Based on our results, we have noted that the bovine and
human forms of factor Xa show different structural responses to
C6PS despite having very similar secondary structures in so-
lution. If their responses to C6PS are different, it could also be
that the location of C6PS binding sites might be different and
our use of data from both bovine N-terminal fragments (Gla,
Gla-EGFN, and Gla-EGFNC) and human C-terminal biosyn-
thetic fragments from cDNA constructs (Xa, GDFXa, E2FXa)
would be flawed. Based on the analysis provided below that is
based on careful inspection of the diagram in Fig. 1 summariz-
ing all our observations, we argue that this is not the case.
Data obtained with the human X fragments clearly show that
a single Ca2-requiring C6PS site exists in E2FXa. The exist-
ence of this site in the catalytic domain was confirmed by our
titration of DEGR-E2FXa fluorescence in the absence of Na

and by titration of the activity of the Y99 mutant of GDFXa in
the absence of Ca2. Titrations of the amidolytic activity of
these biosynthetic human factor Xa fragments show that an-
other site exists in the EGFNC pair and this site regulates
factor Xa activity. This second site was either absent or too
weak to be detected in the absence of Ca2. Because a single
C6PS bound to whole factor Xa and none bound to GDFXa in the
absence of Ca2, there must be a Ca2-masked C6PS binding
site in the Gla domain. The very different responses of whole
factor Xa and GDFXa in the presence of Ca
2 (Fig. 2) to C6PS
shows that linkage of the Gla and EGFNC modules is needed for
a full functional response.
If we consider the experiments done with N-terminal frag-
ments of bovine factor Xa, we see clearly that a Ca
2-masked
C6PS site exists in the Gla domain. We see as well that a single
Ca2-dependent (but not requiring) site exists in Gla-EGFNC.
This site requires the linkage of the Gla, EGFN, and EGFC
modules. Because two C6PS bind to whole bovine factor Xa in
the presence of Ca2, there must be a second site in the cata-
lytic domain.
We argue from this analysis that data obtained with bovine
and human fragments lead independently to nearly the same
conclusions. This means both that the bovine and human pro-
teins interact similarly with C6PS (as expected for such highly
homologous proteins) and that the two sets of data with pro-
teins from different species support and confirm each other.
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